Hosted on MSN

Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization

Michael Morrissey (CEO, President & Director) said the company’s strategy is “to build a multi-franchise business in solid tumor oncology focused on GU and GI histologies,” anchored by cabozantinib ...
ascopubs.org

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion ...

Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from ...
ascopubs.org

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from two dose-escalation cohorts of the phase 1b STELLAR 002 ...

SPYK04, a novel RAF-MEK molecular glue: Dose escalation (DE) in first-in-human study for MAPK pathway-altered solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Yahoo Finance

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization

Christopher Senner (Executive VP & CFO) said, “we are reiterating our full year 2026 financial guidance,” without adding new numerical targets on the call. Dana Aftab (Executive Vice President of ...